Reuters logo
BRIEF-AbbVie says announces high SVR(12) rates with 8 weeks of treatment with its investigational drug
January 9, 2017 / 12:43 PM / in 10 months

BRIEF-AbbVie says announces high SVR(12) rates with 8 weeks of treatment with its investigational drug

Jan 9 (Reuters) - AbbVie Inc

* Eight weeks of treatment with abbvie’s investigational, pan-genotypic, ribavirin-free regimen of glecaprevir/pibrentasvir (G/P) for chronic hepatitis C achieved high SVR rates in genotype 1 Japanese patients

* Says primary endpoint of study was met, as 8 weeks of G/P was shown to be non-inferior to 12 weeks of OBV/PTV/R

* Says in patients treated with OBV/PTV/R, there was one who discontinued treatment due to adverse events Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below